Perspective Therapeutics Inc. (CATX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Perspective Therapeutics Inc. (CATX) has a cash flow conversion efficiency ratio of -0.091x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.47 Million) by net assets ($347.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Perspective Therapeutics Inc. to measure how much of total assets are equity-financed.
Perspective Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how Perspective Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Perspective Therapeutics Inc. (CATX) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Perspective Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Perspective Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tongqinglou Dining Co Ltd
SHG:605108
|
N/A |
|
PRIMA MARINE PCL-NVDR
BK:PRM-R
|
0.098x |
|
Horizon Quantum Holdings Ltd. Class A Ordinary Shares
NYSE:HQ
|
1.695x |
|
BlackRock Municipal Income Closed Fund
NYSE:BFK
|
-0.025x |
|
Vishnu Chemicals Limited
NSE:VISHNU
|
0.085x |
|
Shanghai Morn Electric Equipment Co Ltd
SHE:002451
|
-0.133x |
|
Dalian Thermal Power Co Ltd
SHG:600719
|
0.574x |
|
Long Chen Paper Co Ltd
TW:1909
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Perspective Therapeutics Inc. (1994–2025)
The table below shows the annual cash flow conversion efficiency of Perspective Therapeutics Inc. from 1994 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Perspective Therapeutics Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $207.03 Million | $-82.48 Million | -0.398x | -533.03% |
| 2024-12-31 | $290.67 Million | $-18.29 Million | -0.063x | +87.18% |
| 2023-12-31 | $75.18 Million | $-36.91 Million | -0.491x | -120.42% |
| 2023-06-30 | $54.64 Million | $-12.17 Million | -0.223x | 0.00% |
| 2022-12-31 | $54.64 Million | $-12.17 Million | -0.223x | -77.04% |
| 2022-06-30 | $61.28 Million | $-7.71 Million | -0.126x | 0.00% |
| 2021-12-31 | $61.28 Million | $-7.71 Million | -0.126x | -198.95% |
| 2021-06-30 | $67.41 Million | $-2.84 Million | -0.042x | +81.05% |
| 2020-12-31 | $12.77 Million | $-2.84 Million | -0.222x | +65.09% |
| 2020-06-30 | $5.72 Million | $-3.64 Million | -0.636x | 0.00% |
| 2019-12-31 | $5.72 Million | $-3.64 Million | -0.636x | +3.23% |
| 2019-06-30 | $7.68 Million | $-5.05 Million | -0.657x | 0.00% |
| 2018-12-31 | $7.68 Million | $-5.05 Million | -0.657x | +42.11% |
| 2018-06-30 | $5.03 Million | $-5.71 Million | -1.136x | -110.78% |
| 2017-12-31 | $10.60 Million | $-5.71 Million | -0.539x | 0.00% |
| 2017-06-30 | $10.60 Million | $-5.71 Million | -0.539x | -127.51% |
| 2016-12-31 | $16.40 Million | $-3.88 Million | -0.237x | 0.00% |
| 2016-06-30 | $16.40 Million | $-3.88 Million | -0.237x | -39.74% |
| 2015-12-31 | $20.78 Million | $-3.52 Million | -0.169x | 0.00% |
| 2015-06-30 | $20.78 Million | $-3.52 Million | -0.169x | -25.76% |
| 2014-12-31 | $23.96 Million | $-3.23 Million | -0.135x | 0.00% |
| 2014-06-30 | $23.96 Million | $-3.23 Million | -0.135x | +76.34% |
| 2013-12-31 | $5.37 Million | $-3.06 Million | -0.570x | 0.00% |
| 2013-06-30 | $5.37 Million | $-3.06 Million | -0.570x | -35.37% |
| 2012-12-31 | $5.82 Million | $-2.45 Million | -0.421x | 0.00% |
| 2012-06-30 | $5.82 Million | $-2.45 Million | -0.421x | -12.23% |
| 2011-12-31 | $6.45 Million | $-2.42 Million | -0.375x | 0.00% |
| 2011-06-30 | $6.45 Million | $-2.42 Million | -0.375x | +13.54% |
| 2010-12-31 | $6.20 Million | $-2.69 Million | -0.434x | 0.00% |
| 2010-06-30 | $6.20 Million | $-2.69 Million | -0.434x | -9.39% |
| 2009-12-31 | $9.96 Million | $-3.95 Million | -0.396x | 0.00% |
| 2009-06-30 | $9.96 Million | $-3.95 Million | -0.396x | +19.06% |
| 2008-12-31 | $15.77 Million | $-7.73 Million | -0.490x | 0.00% |
| 2008-06-30 | $15.77 Million | $-7.73 Million | -0.490x | -54.47% |
| 2007-12-31 | $22.72 Million | $-7.20 Million | -0.317x | 0.00% |
| 2007-06-30 | $22.72 Million | $-7.20 Million | -0.317x | +86.94% |
| 2006-12-31 | $2.89 Million | $-7.00 Million | -2.427x | 0.00% |
| 2006-06-30 | $2.89 Million | $-7.00 Million | -2.427x | -276434.01% |
| 2005-06-30 | $11.23 Million | $-9.86K | -0.001x | +99.71% |
| 2004-12-31 | $11.23 Million | $-3.39 Million | -0.301x | -994.03% |
| 2004-06-30 | $-564.20K | $-19.02K | 0.034x | +311.89% |
| 2003-12-31 | $-1.08 Million | $-8.87K | 0.008x | 0.00% |
| 2003-06-30 | $-1.08 Million | $-8.87K | 0.008x | -42.63% |
| 2002-12-31 | $-1.03 Million | $-14.73K | 0.014x | +98.69% |
| 2002-06-30 | $-1.03 Million | $-7.42K | 0.007x | +24.19% |
| 2001-12-31 | $-1.28 Million | $-7.42K | 0.006x | +101.94% |
| 2000-12-31 | $-1.22 Million | $365.34K | -0.298x | -130.95% |
| 1999-12-31 | $-2.14 Million | $275.97K | -0.129x | +42.68% |
| 1999-06-30 | $-1.22 Million | $275.97K | -0.225x | -4087.12% |
| 1998-12-31 | $-2.07 Million | $-11.71K | 0.006x | +3.08% |
| 1998-06-30 | $-2.14 Million | $-11.71K | 0.005x | -99.04% |
| 1997-12-31 | $-1.90 Million | $-1.08 Million | 0.569x | +8.88% |
| 1997-06-30 | $-2.07 Million | $-1.08 Million | 0.523x | -32.96% |
| 1996-12-31 | $-643.46K | $-501.83K | 0.780x | +195.70% |
| 1996-06-30 | $-1.90 Million | $-501.83K | 0.264x | +115.05% |
| 1995-12-31 | $295.71K | $-518.19K | -1.752x | -317.59% |
| 1995-06-30 | $-643.46K | $-518.19K | 0.805x | +145.96% |
| 1994-06-30 | $295.71K | $-518.19K | -1.752x | -- |
About Perspective Therapeutics Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors t… Read more